Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Icahn School of Medicine at Mount Sinai · Stanford University · +9 more institutions
Abstract
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype-directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).
Citation impact
- FWCI
- 50.79
- Percentile
- 100%
- References
- 167
Authors
10- SAStuart A. Scott
Icahn School of Medicine at Mount Sinai
- KSKatrin Sangkuhl
Stanford University
- CMCatherine M. Stein
Vanderbilt University
- JHJ-S Hulot
Inserm, Sorbonne Université, Icahn School of Medicine at Mount Sinai
- JLJessica L. Mega
Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group
Topics & keywords
- CYP2C19
- Clopidogrel
- Medicine
- Percutaneous coronary intervention
- Pharmacogenetics
- Prodrug
- Pharmacology
- Guideline
- Good health and well-being